Frontlight ResearchEarly access
Gastric and oesophageal cancer trials in Switzerland
14 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Where
- Chur, Geneva
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06469944 · EU 2023-509307-33-00 - Phase 1/2Taking peopleSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Where
- Chur, Geneva
- Age
- 18 years and over
- People
- 298 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780111 · EU 2024-514273-22-00 - Phase 1/2Taking peopleA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- Where
- Chur, Geneva
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07405151 · EU 2026-525213-31-00 - Phase 2Taking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Bern, Geneva, Zurich
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - Phase 1/2Taking peopleA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Where
- Chur, Geneva
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05319730 · EU 2023-505189-26-00 - Phase 2WithdrawnStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Basel, Bellinzona, Sankt Gallen
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - No phaseTaking peopleResearch on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors
- Where
- Basel, Biel, Lucerne
- Age
- 18 years and over
- People
- 234
- Run by
- University Hospital, Basel, Switzerland
See details and how to joinNCT07829081 - Phase 1/2Taking peopleSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
- Where
- Chur, Geneva
- Age
- 18 years and over
- People
- 210 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06445972 · EU 2023-509306-29-00 - Phase 1/2Not yet taking people in SwitzerlandFAPI PET Imaging - An Exploratory Study
- Where
- Baden, Geneva, Genolier, Lucerne, Zurich
- Age
- 18 years and over
- People
- 770
- Run by
- Martin Huellner
See details and how to joinNCT07705074 - Phase 1Taking peopleA Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Where
- Chur, Lausanne
- Age
- 18 years and over
- People
- 1,006 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00 - No phaseTaking peopleBalloon Dilation in Patients Undergoing Minimally Invasive Ivor Lewis Esophagectomy and Its Effect on Reducing DGCE
- Where
- Basel
- Age
- 18 years and over
- People
- 116
- Run by
- University Hospital, Basel, Switzerland
See details and how to joinNCT07355374 - Phase 3Taking peoplePROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
- Where
- Villigen, Zurich
- Age
- 18 years and over
- People
- 396 worldwide
- Run by
- University of Aarhus
See details and how to joinNCT05055648 - No phaseTaking peopleStereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
- Where
- Bern, Zurich
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04498767 - No phaseTaking peopleConebeam CT-based Online Adaptive Radio-Therapy for Esophageal Cancer (ARTEC)
- Where
- Bern
- Age
- 18 years and over
- People
- 30
- Run by
- Insel Gruppe AG, University Hospital Bern
See details and how to joinNCT06361043